GB Patent

GB2627096A — Bupivacaine multivesicular liposome formulations and uses thereof

Assigned to Pacira Pharmaceuticals Inc · Expires 2024-08-14 · 2y expired

What this patent protects

Some embodiments of the present application are related to multivesicular liposome formulations comprising high concentration of bupivacaine for the purpose of preventing, treating or ameliorating pain, for example, post-surgical pain for an extended period of time. Processes of …

USPTO Abstract

Some embodiments of the present application are related to multivesicular liposome formulations comprising high concentration of bupivacaine for the purpose of preventing, treating or ameliorating pain, for example, post-surgical pain for an extended period of time. Processes of making and administering bupivacaine encapsulated multivesicular liposome formulations (BUP-MVLs) and their uses as medicaments are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
GB2627096A
Jurisdiction
GB
Classification
—
Expires
2024-08-14
Drug substance claim
No
Drug product claim
No
Assignee
Pacira Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.